ECG vs EXPO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ECG is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ECG and EXPO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ECG and EXPO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Everus Construction Group is a specialty construction and infrastructure services company headquartered in Bismarck, North Dakota. It operates through roughly 15 wholly owned operating companies that go to market under local brands, organized into two segments. The Electrical & Mechanical (E&M) segment installs and maintains electrical and communication wiring, fire-suppression systems, mechanical piping, and renewables infrastructure for commercial, industrial, and public customers. The Transmission & Distribution (T&D) segment builds and maintains overhead and underground electrical, gas, and communication lines, plus transportation lighting, and manufactures line-construction tools and equipment. A major growth driver is data center construction, where the company cites more than 14 years of experience and strong, visible demand from large customers.

Full ECG guide

Exponent, Inc. is a Menlo Park, California engineering and scientific consulting firm founded in 1967 that solves complex technical problems for corporations, law firms, insurers, and government agencies. Its two segments are Engineering and Other Scientific (roughly 85% of net revenues), covering failure analysis, product testing, user research, and disputes across consumer electronics, energy, utilities, transportation, and life sciences, and Environmental and Health (about 15%). The business is people-based rather than asset-based, so its economics revolve around billable hours, staff utilization, and realized billing rates, and its brand as a science-for-hire authority lets it command premium fees on reactive, high-stakes engagements.

Full EXPO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ECG drivers: Data center and electrification demand; Record backlog and raised guidance.
• EXPO drivers: Reactive and disputes demand; AI-enabled products and new risk categories.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a construction contractor, Everus is cyclical and sensitive to interest rates, project financing, and customer capital-spending cycles, so a slowdown in data center or infrastructure investment would hit new bookings. For EXPO, exponent's output is entirely dependent on attracting and retaining specialized PhD-level and engineering talent, so wage inflation, attrition, or hiring shortfalls directly pressure capacity and margins.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ECG if you believe its drivers more; EXPO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ECG and EXPO guides.

ECG. Figures are approximate and tied to the asOf date; verify live numbers before acting. Everus trades at a meaningful premium to traditional construction peers on both P/E (in the mid-30s) and EV/EBITDA (around 25x versus a longer-run construction median closer to the mid-teens), reflecting its data center and electrification growth. The valuation already embeds continued backlog conversion and margin gains, so the figures matter most as a gauge of how much optimism is priced in.

EXPO. Exponent's Q1 2026 revenue rose about 14% to roughly $166 million with net income up 11% to about $30 million, aided by 76% utilization and roughly 399,000 billable hours. The shares typically trade at a rich valuation, with a trailing P/E in the low-to-mid 30s, reflecting the market's view of the franchise as a durable, high-quality compounder. The company continues to return cash aggressively, paying dividends and repurchasing stock while expanding its buyback authorization.

Headline figures (approximate, July 2026): ECG shows revenue (fy 2025) ~$3.75 billion, up ~31%, net income (fy 2025) ~$202 million, up ~41%, 2026 revenue guidance ~$4.1 to $4.2 billion, backlog ~$3.68 billion after Q1 2026; EXPO shows revenue (ttm, gross) ~$580M, q1 2026 revenue ~$166M (+14% YoY), q1 2026 eps (diluted) ~$0.59, ebitda margin (net rev.) ~28%.

ECG and EXPO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ECG and EXPO exposure against your real portfolio. It is not an investment adviser.